Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback